title: Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine.
abstract: A new formulation of zolmitriptan has been developed that dissolves on the tongue without the need for additional fluid intake. In this double-blind, parallel study, 471 patients were randomized to receive the zolmitriptan orally disintegrating tablet 2.5 mg (n=231) or matching placebo (n=240) to treat a single moderate or severe migraine. Headache relief following zolmitriptan 2.5 mg (63%) was significantly greater than with placebo (22%) at 2 h post-dose (primary endpoint; P < 0.0001). The zolmitriptan orally disintegrating tablet was also significantly more effective than placebo for 1-, 2- and 4-h pain-free response (8% vs. 3%, P=0.0207, 27% vs. 7%, P < 0.0001, and 37% vs. 11%, P < 0.0001, respectively). Of those patients stating a preference, 70% of patients preferred the orally disintegrating tablet to a conventional tablet. Zolmitriptan orally disintegrating tablets are an effective and convenient alternative to a conventional tablet, allowing migraine attacks to be treated anytime a migraine strikes, which can facilitate earlier treatment.
authors.affiliation: The Kings Headache Services, Kings College Hospital, London, UK. ANDYDOWSON@DOWSONA.fsnet.co.uk
authors.forename: A J
authors.initials: AJ
authors.lastname: Dowson
authors.forename: E A
authors.initials: EA
authors.lastname: MacGregor
authors.forename: R A
authors.initials: RA
authors.lastname: Purdy
authors.forename: W J
authors.initials: WJ
authors.lastname: Becker
authors.forename: J
authors.initials: J
authors.lastname: Green
authors.forename: S L
authors.initials: SL
authors.lastname: Levy
mesh_terms: D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D023303:Oxazolidinones / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D010166:Palliative Care; D017060:Patient Satisfaction; D012008:Recurrence; D019233:Retreatment; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D012995:Solubility; D014363:Tryptamines
chemical_list: D023303:Oxazolidinones; D017366:Serotonin Receptor Agonists; D014363:Tryptamines; C089750:zolmitriptan